I. TỔNG QUAN PHƯƠNG PHÁP
A. Tiếng Việt
1, Đặng Thành Nam, Phan Văn Chi (2006) Nghiên cứu hệ protein huyết thanh bệnh nhân viêm gan B bằng phương pháp sắc ký lỏng nano đa chiều kết hợp khối phổ liên tục. Tạp chí Công nghệ Sinh học 4(2):159-70.
2, Đỗ Trung Phấn (2003). Lơ xê mi cấp - Bệnh lý tế bào nguồn tạo máu. NXB Y học, Hà Nội.
3, Đỗ Trung Phấn (2004). Bài giảng huyết học-truyền máu. NXB Y Học, Hà Nội.
4, Hoàng Đăng Mịch (2006). Nồng độ CRP với tế bào mấu ngoại vi, BMI và thời gian mắc bệnh đái tháo đường týp 2. Hội nghị khoa học Hóa Sinh Y Dược học, Hải Phòng, 8/2006:59- 65.
5, Lâm Thị Mỹ, Trần Thái Bình, Nguyễn Thanh Hưng, Huỳnh Nghĩa (2004). Đặc điểm bệnh bạch cầu cấp ở trẻ em khu vực phía nam năm 2002-2003. Tạp chí Y học thành phố Hồ Chí Minh 1(8):98-102.
6, Nguyễn Anh Trí, Nguyễn Hữu Toàn (1995). Từ tiền leukemia đến leukemia cấp. NXB Y học, Hà Nội-1995.
7, Nguyễn Hữu Chí (1997). Một sốđặc điểm của bệnh viêm gan siêu vi. Nhà xuất bản TP Hồ
Chí Minh, 1997.
8, Nguyễn Nam Long, Nguyễn Bích Nhi, Phạm Vân Anh, Phan Văn Chi (2006). Phân tích hệ
protein huyết thanh của một bệnh nhân mang đột biến A3442G trong gen tRNALeu ty thể.
Tạp chí Y học Việt Nam số 325(8):24-28.
9, Nguyễn Ngọc Dũng, Nguyễn Anh Trí (2007). Một sốđặc điểm lâm sàng bệnh Lơ-xê-mi kinh dòng hạt giai đoạn Lơ-xê-mi cấp thực sự. Tạp chí Y học thực hành (10):11-13.
10, Nguyễn Thị Minh Phương, Trần Thế Thành, Nguyễn Bích Nhi, Phan Văn Chi (2007). Phân tích sự thay đổi của các glycoprotein trong huyết thanh bệnh nhân đái tháo đường type 2. Tạp chíSinh học 29(3):90-94.
11, Nguyễn Thị Phương Mai, Trần Hoài Nam, Đào Văn Tùng (2006). Giá trị HbA1c, huyết thanh trong chẩn đoán đái tháo đường tại Bệnh viện Việt Tiệp – Hải Phòng. Hội nghị khoa học Hóa Sinh Y Dược học, Hải Phòng, 8/2006, tr.92-9.
12, Nguyễn Triệu Vân, Nguyễn Quang Tùng, Nguyễn Anh Trí, Đỗ Trung Phấn và cộng sự
(2004). Giá trị của một số dấu ấn miễn dịch (markers) trong chẩn đoán phân loại lơ xê mi cấp dòng lympho người lớn tại Viện huyết học truyền máu. Báo cáo khoa học Viện huyết học truyền máu, Hà Nội-2004.
13, Phan Văn Chi (2003). Khối phổ trong nghiên cứu Proteomics. Tạp chí Công nghệ Sinh học
1(1):11-24.
14, Phan Văn Chi (2003). Proteomics và những nghiên cứu ứng dụng. Tạp chí Công nghệ Sinh học 1(4):397-414.
15, Phan Văn Chi (2006). Proteomics, Khoa học về hệ protein. NXB Viện KH&CNVN, Hà Nội-2006
16, Tạ Văn Bình (2006). Bệnh đái tháo đường-tăng glucose máu. NXB Y học, Hà Nội-2006.
17, Tạ Văn Bình (2006). Dịch tễ học bệnh đái tháo đường ở Việt Nam, các phương pháp điều trị
104 18, Thái Quí (1997). Leucemie cấp trong Bài giảng Bệnh ung thư (Tập 2) NXB Y học, tr.194-
207.
19, Trần Thị Minh Hương, Đỗ Trung Phấn (2002). Tình hình bệnh máu tại Viện huyết học – Truyền máu, Bệnh Viện Bạch Mai. Kỷ yếu công trình nghiên cứu Khoa học Huyết học – Truyền máu 1999 – 2000, NXB Y học: 15- 24.
20, Vũ Minh Thiết, Nguyễn Bích Nhi, Phan Văn Chi (2006). Phân tích hệ protein huyết thanh của một bệnh nhân suy tủy xương cấp. Tạp chí Y học Việt Nam 324(7):40-4.
21, Vũ Minh Thiết, Nguyễn Nam Long, Đặng Thành Nam, Phan Văn Chi (2004). Nghiên cứu hệ
protein huyết thanh người bằng sắc ký lỏng đa chiều kết hợp với khối phổ MS/MS, BCKH Hội Nghị Toàn Quốc 2004, NCCB Đinh hướng Y-Dược học, Học viện Quân Y, Hà Nội, 27- 27/10/2004, tr.470-4.
22, Vũ Minh Thiết, Trần Thế Thành, Nguyễn Thị Minh Phương, Phan Văn Chi (2006). Phân tích các glycoprotein trong huyết thanh người. Tạp chí Công nghệ Sinh học 4(1):13-22.
B. Tiếng Anh
1, Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, Sandeep S, Radha V, Deepa R,
Mohan V (2005). ENPP1/PC-1 K121Q Polymorphism and Genetic Susceptibility to Type 2
Diabetes. Diabetes 54:1207-13.
2, Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG (2002). Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1:947-55.
3, Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198-207.
4, Alexander H, Stegner AL, Wagner-Mann. C, Du Bois GC, Alexander S, Sauter ER (2004). Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clinical Cancer Research 10(22):7500-10.
5, Anderson L (2005). Candidate-based proteomics in the search for biomarkers of cardiovascular disease. Journal of Physiology 563:23-60.
6, Anderson NL, Anderson NG (1998). Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis 19:1853-61.
7, Anderson NL, Anderson NG (2002). The human plasma proteome, history, character and diagnostic prospects. Mol Cell Proteomics 1: 845-67.
8, Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004). The Human Plasma Proteome: A Nonredundant List Developed by Combination of Four Separate Sources. Mol Cell Proteomics 3:311-26.
9, Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics 25:25-9.
10, Austin MJF, Babiss L (2006) Commentary: Where and How Could Biomarkers Be Used in 2016. AAPS Journal 8(1): E185-E189; DOI: 10.1208/aapsj080122
11, Ayton PM and Cleary ML (2001). Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20(40):5695-707.
12, Banks RE, Dunn MJ, Hochsrasser DF, Sachez JC, Blackstock B, Pappin DJ & Selby PJ (2000). Proteomics: new perspectives, new biomedical opportunities. Lancet 356:1749-56.
105 13, Bavelloni A, Faenza I, Cioffi G, Piazzi M, Parisi D, Matic I, Maraldi NM and Cocco L (2006). Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. Proteomics 6:5725-34.
14, Bégay-Müller V, Ansieau S, Leutz A (1999). The LIM domain protein Lmo2 binds to AF6, a translocation partner of the MLL oncogene. FEBS Letters 521(1):36-38.
15, Bennett JM (2000). World health organization classification of the acute leukemia and myelodysplastic syndrome. Int J Hematol (72):131-33.
16, Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976). Proposals for the classification of the acute leukaemias. French-American-British (FAB) co- operative group. Br J Haematol 33(4):451-58.
17, Bichsel VE, Liotta LA, Petricoin EF (2001). Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7:69-78.
18, Bishop JR, Erin F, Roger L, Jeffrey DE (2010). Insulin-dependent Diabetes Mellitus in Mice Does Not Alter Liver Heparan Sulfate. J Biol Chem 285:14658-62.
19, Bollag DM, Rozycki D, Edelstein SJ(1996). Protein Methods, 2nd ed. New York, N.Y: John Wiley & Sons, Inc.
20, Bourguignon LY, Zhu H, Shao L, Chen YW (2000). Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. Journal of Cell Biology 150(1):177-91.
21, Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem 72:248-54.
22, Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, and Gromova I (2004). Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.
Mol Cell Proteomics 3(4): 327-44.
23, Chan KC, Lucas DA, Hise D, Schaefer CF, Xiao Z, Janini GM, Kenneth HB, Haleem JI, Veenstra TD, Conrads TP (2004). Analysis of the Human serum proteome. Clinical Proteomics 1(2):101-25.
24, Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, Housman D (2003). Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37:58-71.
25, Chauhan G, Charles JS, Tabassum R, Bhaskar S, Smita RK, Mahajan A, Chavali S, Kumar K, Prakash S, Dwivedi OP, Ghosh S, Chittaranjan SY, Tandon N, Bharadwaj D, Giriraj RC (2010). Impact of Common Variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX,
CDKN2A, IGF2BP2, and CDKAL1 on the Risk of Type 2 Diabetes in 5,164 Indians.
Diabetes 59(8):2068-74.
26, Chen H, Antonarakis SE (1995). Localization of a human homolog of the mouse Tiam-1 gene to chromosome 21q22. Genomics 30(1):123-7.
27, Cheng JC, Esparza S, Sandoval S, Shankar D, Fu C and Sakamoto KM (2007). Potential role of CREB as a prognostic marker in acute myeloid leukemia. Future Oncol 3(4):475-80.
28, Choughule A, Polampalli S, Amre P, Shinde S, Banavali S, Prabhash K, Nair R,
Subramanian PG, Gujral S and Parikh PM (2009). Identification of PML/RARα fusion gene
transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ
hybridization. Genetics and Molecular Research 8(1):1-7.
106 29, Compton SJ, Jones CG (1985). Mechanism of dye response and interference in the Bradford
protein assay. Anal Biochem 151:369-74
30, Congrong W, Cheng H, Rong ONG Z, Yuqian B, Xiaojing M, Jingyi I L, Wen Q, Xinyu S, Junxi L, Jing X, Hụiuan L, Kunsan X, Weiping J (2009). Common Variants of Hepatocyte Nuclear Factor 1β Are Associated With Type 2 Diabetes in a Chinese Population. Diabetes
58:1023-27.
31, Cui JW, Li WH, Wang J, Li AL, Li HY, Wang HX, He K, Li W, Kang LH, Yu M, Shen BF, Wang GJ, Zhang XM (2005). Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4(11):1718-24.
32, Cui JW, Wang J, He K, Jin BF, Wang HX, Li W, Kang LH, Hu MR, Li HY, Yu M, Shen BF, Wang GJ, Zhang XM. (2004). Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 10(20):6887-96.
33, Dearden CE, Matutes E, Cazin B (2001). High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98 (6):1721–6.
34, Deng LW, Chiu I, Strominger JL (2004). MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. Proc Natl Acad Sci USA 101:757-762.
35, Dennis TV, Robertson H, Graeme IB, Bruce W P, Tran H, Wice B, Kenneth SP (2010). TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action. Diabetes 59(2):479-85.
36, Dhiman G, Oleg K, Mihaela A, Werner E, Kenneth G. S., Ronald C. B, John AW (2004). Lectin Affinity as an Approach to the Proteomic Analysis of Membrane Glycoproteins.
Journal of proteome research 3:841-50.
37, Diamandis EP (2007). Oncopeptidomics: A Useful Approach for Cancer Diagnosis? Clinical Chemistry 53(6):1004-06.
38, Diamandis EP (2004). Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3:367–78.
39, Domer PH et al (1993). Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL- AF4 fusion product. Proc Natl Acad Sci USA 90(16): 7884-8.
40, Domon B, Aebersold R (2006). Mass spectrometry and protein analysis. Science 312: 212- 17.
41, Dorrie J, Sapala K, Zunino SJ (2002). Interferon-gamma increases the expression of glycosylated CD95 in B-leukemic cells: an inducible model to study the role of glycosylation in CD95-signalling and trafficking. Cytokine 18(2):98-107.
42, Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM (2002) MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 21:4849-54.
43, Fang FM, Friedrichsm WE, Cupples RL, Bonifacio MJ, Sanford JA., Horton WA, Bowman BH (1990). Human ceruloplasmin. Tissue-specific expression of transcripts produced by alternative splicing. J Biol Chem, 265 (18):10780-5.
44, Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE and Lange BJ (1995). ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood
Volume 85, Issue 11:3250-6.
45, Fujiki R, Chikanishi T, Hashiba W, Ito H, Takada I, Roeder RG, Kitagawa H, Kato S (2009). GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature
107 46, Ganda OP, Arkin CF (1992 ) Hyperfibrinogenemia, an important risk factor for vascular
complications in diabetes. Diabetes Care 15: 1245-50.
47, Giampietro G, Daniel FH (2006). Biomarkers in Breast Cancer, Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect. Humana Press:18-20
48, Gomez JA, del Pozo C, Sorribas A, Serrat J, Gonzalez-Sastre F, de Leiva A (1989) Apolipoprotein C subtype distribution in type 2 diabetes mellitus. Diabet Med, 6(2):127-130.
49, Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W (2000). The current state of two-dimensional electrophoresis with immobilized pH gradients.
Electrophoresis 21:1037-53.
50, Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, Toropygin IY, Vlasova MA, Safarova MR, Makarov OV, Archakov AI (2006). Two- dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry (Mosc) 71(4):354-60.
51, Grignani F, Gelmetti V, Fanelli M, Rogaia D, De Matteis S, Ferrara FF, Bonci D, Grignani F, Nervi C, Pelicci PG (1999). Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response. Oncogene 18(46):6313-21.
52, Gromov PS, Ostergaard M, Gromova I, Celis JE (2002). Human proteomic databases: a
powerful resource for functional genomics in health and diesease. Prog Biophys Mol Biol
80:3-22.
53, Habets GG, van der Kammen RA, Stam JC, MichielsF, Collard JG (1995). Sequence of the human invasion-inducing TIAM1 gene, its conservation in evolution and its expression in tumor cell lines of different tissue origin. Oncogene 10(7):1371-6.
54, Harper RG, Workman SR, Schuetzner S, Timperman AT, Sutton JN (2004). Low molecular weight human serumproteome usingultrafiltration, isoelectric focusing, and mass spectrometry. Electrophoresis 25:1299-306.
55, Harris NL, Jaffe ES, Diebold J et al (1999). World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie house, Virginia, November 1997. J Clin Oncol (17):3835-49.
56, He QY, Chiu JF (2003). Proteomics in biomarker discovery and drug development. Journal of Cell Biochemistry 89:868-86.
57, Heerema NA, Arthur DC, Sather H, Albo V, Feisner. J, Lange BJ, Steinherz PG, Zeltzer P, Hammond D, Reaman GH (1994). Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. Blood 83(8):2274-84.
58, Hongfang L, Ying Y, Emma MA, Nadeeja W, Michael BW (2008). The Identification of Potential Factors Associated with the Development of Type 2 Diabetes: A Quantitative Proteomics Approach. Mol Cell Proteomics 7:1434-51.
59, Hortin GL (2007). A New Era in Protein Quantification in Clinical Laboratories: Application of Liquid Chromatography-Tandem Mass Spectrometry. Clin Chem 53(4): 543-44.
60, Hortin GL, Jortani SA, Ritchie JC Jr, Valdes R Jr, Chan DW (2006). Proteomics: A New Diagnostic Frontier. Clin Chem 52(7):1218-22.
61, Hou M, Tan L, Wang X, Zhu YS (2004). Antisense Tiam1 down-regulates the invasiveness of 95D cells in vitro. Acta Biochim Biophys Sin (Shanghai)36(8):537-40.
108 62, Huang CJ, Gurlo T, Haataja L, Costes S, Daval M, Ryazantsev S, Xiuji Wu, Alexandra E.
Butler, Peter C (2010). Calcium-activated Calpain-2 Is a Mediator of Beta Cell Dysfunction and Apoptosis in Type 2 Diabetes.J Biol Chem 285:339-48.
63, Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, Mogg M, Schreiber M, Feuerstein I, Huck CW, Stecher G, Bonn GK, Huber LA (2006). Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI- TOF/TOF and data validation by routine clinical assays. Electrophoresis 27(8):1641-50.
64, Ideker T, Sharan R (2008). Protein networks in disease. Genome Res 18(4):644-52.
65, Imanishi T, Itoh T, Suzuki Y et al (2004). Integrative Annotation of 21,037 Human Genes Validated by Full-Length cDNA Clones. PLoS Biol 2(6):1-20.
66, Jain S, Rajput A, Kumar Y, Arvind AS, Tatu U (2005). Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 53: 513- 20.
67, Jameson JN St C, Dennis L Kasper, Harrison, Tinsley Randolph, Braunwald, Eugene, Fauci, Anthony S, Hauser, Stephen L, Longo, Dan L (2005). Harrison's principles of internal medicine. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-140235-7.
68, Jensen ON (2004). Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry.Current Opinionin ChemicalBiology8:33-41.
69, Jiang H, Guan G, Zhang R, Liu G, Cheng J, Hou X, Cui Y (2009). Indentification of urinary soluble E-cadherin as a novel biomarker for diabetic nepharopathy. Diabetes Metab Res Rev
25(3): 232-41.
70, Joly E, Roduit R, Peyot ML, Habinowski SA, Ruderman NB, Witters LA, Prentki M (2009). Glucose represses PPAR gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic β-cell. J Diabetes 1(4):263-72.
71, Kakizuka A, Miller WHJ, Umesono K et al (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-74.
72, Kappelmayer J, Udvardy M, Antal-Szalmás P (2007). Pgp and FLT3: identification and modulation of two proteins that lead to chemotherapy resistance in acute myeloid leukemia.
Curr Med Chem14(5):519-30.
73, Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, DeRyckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson
